Biohaven Insiders Buy More Shares – Insider Weekends

Biohaven (BHVN): $38.97

Market Cap: $3.44B

Enterprise Value: $3.09B

Key Insights:

• “New” Biohaven was created when Pfizer spun-out the product portfolio it did not retain after acquiring “old” Biohaven for its migraine treatments.
• Biohaven retained its CEO, was funded with $275 million in cash by Pfizer and was entitled to certain royalty payments.
• We saw insider buying even before Pfizer’s acquisition of old Biohaven was complete and the insider buying continued in new Biohaven after the spinoff.

Only plus or premium subscribers can access this post. Subscribe today.